Axcelead Chief Says Small-Molecule Drug Targets More than Doubled in Last Few Years; IPO Eyed in 4-5 Years

Axcelead President Yoshinori Ikeura Advances in drug discovery technology have made it possible for small-molecule compounds to target proteins that they could not target before, Yoshinori Ikeura, president of Axcelead Drug Discovery Partners, tells Jiho. While many industry observers say...read more